FDA panel favors Pfizer's Prevnar 13 for expanded use

An FDA advisory panel backed Pfizer's ($PFE) Prevnar 13 vaccine for use in adults age 50 and older to stave off pneumonia, meningitis, and other pneumococcal infections. The committee voted 14-1 in favor of the new indication, and the FDA plans to make its final decision in January. Report